浏览全部资源
扫码关注微信
1.亳州市中医院,安徽 亳州 236800
2.安徽省中医院,合肥 230031
董建华,硕士,副主任中医师,从事儿科肾脏免疫疾病的研究,E-mail:wwwdjh201010@163.com
陈永宏,硕士,副主任医师,从事肾脏免疫疾病的研究,E-mail:yh7053@163
纸质出版日期:2021-01-20,
网络出版日期:2020-07-27,
收稿日期:2020-06-13,
扫 描 看 全 文
董建华,王祖亮,夏永光等.紫癜汤加减对儿童紫癜性肾炎免疫炎症因子的调节作用[J].中国实验方剂学杂志,2021,27(02):104-109.
DONG Jian-hua,WANG Zu-liang,XIA Yong-guang,et al.Study on Regulatory Action of Addition and Subtraction of Therapy of Zidiantang to Mmune Inflammatory Factors of Children with Purpura Nephritis[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(02):104-109.
董建华,王祖亮,夏永光等.紫癜汤加减对儿童紫癜性肾炎免疫炎症因子的调节作用[J].中国实验方剂学杂志,2021,27(02):104-109. DOI:
DONG Jian-hua,WANG Zu-liang,XIA Yong-guang,et al.Study on Regulatory Action of Addition and Subtraction of Therapy of Zidiantang to Mmune Inflammatory Factors of Children with Purpura Nephritis[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(02):104-109. DOI:
目的
2
观察紫癜汤加减治疗儿童紫癜性肾炎(血热妄行证)的临床疗效及对免疫炎症因子的调节作用。
方法
2
将125例患儿采用随机按数字表法分为对照组61例和观察组64例。对照组脱落、失访问2例,剔除2例,最后完成57例;观察组脱落、失访3例,剔除2例,最后完成59例。两组均给予西医综合治疗措施。对照组口服血尿安胶囊,1~4粒/次,3次/d;观察组以紫癜汤加减辨证内服,1剂/d。两组疗程均为2个月,疗程结束后随访1个月。每周记录1次紫癜情况、进行1次尿液分析检测,记录3个月内紫癜、血尿和蛋白尿消失情况;治疗前、治疗后1个月,2个月和随访1个月进行24 h尿蛋白定量(24 hUp)检查和血热妄行证评分;检测治疗前后尿微量白蛋白(mAlb),尿
β
2
微球蛋白(
β
2
-MG),胱抑素 C(CysC),免疫球蛋白A1(IgA1),IgG,补体C3,CD4
+
,辅助性T细胞(Th)17细胞,Treg细胞,白细胞介素-17(IL-17),IL-21,IL-10和转化生长因子-
β
1
(TGF-
β
1
)水平。
结果
2
治疗后1个月,观察组紫癜消失率高于对照组(
P
<
0.05);治疗后1,2个月和随访1个月观察组血尿和蛋白尿消失率均高于对照组(
P
<
0.05);治疗后1,2个月和随访1个月,观察组24 hUp水平和血热妄行证积分均低于对照组(
P
<
0.01);观察组mAlb,
β
2
-MG和CysC水平均低于对照组(
P
<
0.01);观察组IgA1,IgG均低于对照组(
P
<
0.01),C3高于对照组(
P
<
0.01);观察组CD4
+
,Treg均高于对照组(
P
<
0.01),Th17和Th17/Treg均低于对照组(
P
<
0.01);观察组IL-17,IL-21,和TGF-
β
1
均低于对照组(
P
<
0.01),IL-10水平高于对照组(
P
<
0.01)。
结论
2
在常规西医治疗的基础上,采用紫癜汤加减辨证治疗HSPN血热妄行证患儿,可促进紫癜消退,改善血热妄行证症状,能调节免疫炎症反应,减轻了肾脏炎性损伤,从而减轻了血尿和蛋白尿,起到了保护肾功能作用。
Objective
2
To observe clinical effect of addition and subtraction therapy of Zidiantang to purpura nephritis in children (syndrome of blood fever) and regulatory action to immune inflammatory factors.
Method
2
One hundred and twenty-five patients were randomly divided into control group (61 cases) and observation group (64 cases) by random number table. A total of 57 patients in control group completed the therapy (2 patients were falling off or missing visit and 2 was eliminated), 59 patients in observation group completed the therapy (3 patients were falling off or missing visit and 2 was eliminated). Both groups' patients got comprehensive measures of western medicine. Patients in control group got Xueniaoan capsule, 1 to 4 grains/time, 3 times/day. Patients in observation groups got addition and subtraction therapy of Zidiantang, 1 dose/day. The treatment was continued for 2 months and the follow up was recorded for a month. Purpura and urinalysis were recorded for every week. And disappearance of purpura, hematuria and proteinuria were compared for 3 months. Before treatment, and at the first, second and during the follow up, scores of 24 h urine protein quantification (24 hup) and syndrome of blood fever were graded. Levels of microalbuminuria (mAlb), urinary
β
2
-microglobulin (
β
2
-MG), cystatin C(CysC), globulin A1(IgA1), IgG, complement C3, Th17 cells, Treg cells, interleukin-17 (IL-17), IL-21, IL-10 and transforming growth factor-
β
1
(TGF-
β
1
) were detected before and after treatment.
Result
2
At the first month of treatment, disappearance rate of purpura in observation group was higher than that in control group (
P
<
0.05). Before treatment, and at the first, second and during the follow up, disappearance rate of hematuria and albuminuria were higher than those in control group (
P
<
0.05), and scores of 24 h urine protein quantification (24 hup) and syndrome of blood fever were lower than those in control group (
P
<
0.01). Levels of mAlb,
β
2
-MG, CysC, IgA1, IgG, Th17, Th17/Treg, IL-17, IL-21 and TGF-
β
1
were lower than those in control group (
P
<
0.01), and levels of C3, CD4
+
, Treg and IL-10 were higher than those in control group (
P
<
0.01).
Conclusion
2
On the basis of conventional western medicine treatment, addition and subtraction therapy of Zidiantang can promote the purpura to subside, improve the syndrome symptoms of blood fever, regulate the immune inflammatory reaction, reduce the inflammatory damage of kidney, thus reduce the hematuria and proteinuria, and play a role in protecting the renal function.
紫癜性肾炎血热妄行证紫癜汤肾功能免疫球蛋白Treg细胞Th17细胞
purpura nephritissyndrome of blood feverZidiantangrenal functionimmunoglobulinTreg cellsTh17 cells
李雪倩,刘小荣,姚兴凤,等.牛津分类与国际小儿肾脏病研究组分级在评价儿童紫癜性肾炎预后中的应用[J].中华肾脏病杂志,2020,36(1):26-33.
高春林,章丹,夏正坤,等.2004—2017年单中心9925例儿童肾活检病理分析[J].中华肾脏病杂志,2019,35(3):177-183.
HEINEKE M H, BALLERING A V, JAMINA,et al.New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura) [J].Autoimmun Rev,2017,16(12):1246‐1253.
张文曦.邹燕勤论治过敏性紫癜性肾炎经验[J].中医杂志,2018,59(18):1546-1549.
张婧,张海力,高彤彤,等.吕仁和“二五八”方案及“三期九度”法辨治过敏性紫癜肾炎经验[J].北京中医药,2020,39(1):18-23.
施蕾,庞礴,许琳洁,等.中医药治疗儿童过敏性紫癜性肾炎的研究进展[J].中华中医药杂志,2019,34(2):708-710.
孙一民.临证医案医方[M].郑州:河南科技出版社,1981:45-46.
杨淑莲,周振环,杜昊.紫癜汤治疗紫癜性肾炎25例[J].中国中医急症,2010,19(7):1229-1230.
中华医学会儿科学分会肾脏学组.紫癜性肾炎诊治循证指南(2016)[J].中华儿科杂志,2017,55(9):647-651.
中华中医药学会.中医内科常见病诊疗指南(西医疾病部分)[M].北京:中国中医药出版社,2008:187-189.
张爱华,朱春华.儿童紫癜性肾炎诊治进展[J].中华实用儿科临床杂志,2017,32(5):324-327.
张腾飞,邵晓珊.儿童紫癜性肾炎病因及免疫机制研究进展[J].贵州医药,2019,43(2):206-210.
覃玉芳,李贵平.加味犀角地黄汤辨治儿童紫癜性肾炎血热夹瘀证的临床观察[J].中国实验方剂学杂志,2019,25(2):144-149.
卢积坪,李红毅,党若楠,等.禤国维教授治疗儿童过敏性紫癜性肾炎经验[J].中国医药导报,2019,16(36):149-152.
刘玉清,丁樱,翟文生,等.小儿过敏性紫癜性肾炎肾脏病理分级与中医辨证的关系[J].安徽中医学院学报,2011,30(5):30-32.
PILLEBOUT E, JAMIN A, AYARI H, et al. Biomarkers of IgA vasculitis nephritis in children[J].PLoS One,2017,12(11):e0188718.
BOSE S, PATHIREDDY S, BARADHI K M, et al.Seizures, renal failure and acute respiratory failure: not your typical case of Henoch-Schonlein purpura[J].BMJ Case Rep,2019,12(7):e229939.
YANG B, TAN X, XIONG X, et al. Effect of CD40/CD40 L signaling on IL-10-producing regulatory B cells in Chinese children with Henoch-Schönlein purpura nephritis[J].Immunol Res,2017,65(3):592‐604.
XU H, PAN Y, LI W, et al. Association between IL17A and IL17 F polymorphisms and risk of henoch-schonlein purpura in Chinese children[J].Rheumatol Int,2016,36(6):829‐835.
杨新凤,王会荣,田浩,等.过敏性紫癜患儿血清IL-21,TGF-β1,TNF-α及IgA1水平与紫癜性肾炎发生的相关性研究[J].现代生物医学进展,2017,17(22):4295-4298.
0
浏览量
10
下载量
2
CSCD
关联资源
相关文章
相关作者
相关机构